Objective: To evaluate the effect of inhaled steroids on the heart rate variability in pediatric patients with asthma. Materials and Methods: The study included 17 pediatric patients with asthma using inhaled steroids and a control group of 17 healthy, ageand gender-matched children. A 24-hour Holter monitor was applied and the time domain and frequency domain parameters of heart rate variability were examined. The values were obtained for night, day, and a 24 hour cycle. Results: No statistically significant difference was found between asthmatic children treated with inhaled steroids and the control group in regards to night, day, and whole day values of the time and frequency domain parameters of heart rate variability. Conclusion: There was no change in the variability of heart rate of pediatric asthma patients with symptoms under control by inhaled steroids.
{"title":"Is There An Effect of Inhaled Steroid Treatment on Heart Rate?","authors":"M. Y. Özkars, M. Argun","doi":"10.21911/AAI.414","DOIUrl":"https://doi.org/10.21911/AAI.414","url":null,"abstract":"Objective: To evaluate the effect of inhaled steroids on the heart rate variability in pediatric patients with asthma. Materials and Methods: The study included 17 pediatric patients with asthma using inhaled steroids and a control group of 17 healthy, ageand gender-matched children. A 24-hour Holter monitor was applied and the time domain and frequency domain parameters of heart rate variability were examined. The values were obtained for night, day, and a 24 hour cycle. Results: No statistically significant difference was found between asthmatic children treated with inhaled steroids and the control group in regards to night, day, and whole day values of the time and frequency domain parameters of heart rate variability. Conclusion: There was no change in the variability of heart rate of pediatric asthma patients with symptoms under control by inhaled steroids.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46882511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dried thyme, black pepper and honey are widely used worldwide. However, systemic allergic reactions to these substances are rarely reported. Here we report a 45-year-old case with multiple severe anaphylaxis to thyme, black pepper, honey and wasp, that occurred at different times. Her reactions to thyme, black pepper and wasp were IgE-mediated as confirmed with skin prick tests and/or serology. It was not possible to determine the underlying etiology of her honey allergy. Still, with her history and the risk of systemic reactions with bee secretions and/or pollen protein content of honey, she was advised not to consume any traces of the causative foods and informed about bee avoidance.
{"title":"A Rare Case of Multiple Severe Anaphylaxis Caused by Thyme, Black Pepper, Wasp and Honey","authors":"M. Türk, I. Yilmaz","doi":"10.21911/AAI.448","DOIUrl":"https://doi.org/10.21911/AAI.448","url":null,"abstract":"Dried thyme, black pepper and honey are widely used worldwide. However, systemic allergic reactions to these substances are rarely reported. Here we report a 45-year-old case with multiple severe anaphylaxis to thyme, black pepper, honey and wasp, that occurred at different times. Her reactions to thyme, black pepper and wasp were IgE-mediated as confirmed with skin prick tests and/or serology. It was not possible to determine the underlying etiology of her honey allergy. Still, with her history and the risk of systemic reactions with bee secretions and/or pollen protein content of honey, she was advised not to consume any traces of the causative foods and informed about bee avoidance.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49400578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The use of other mammals’ milk as an alternative treatment of cow’s milk allergy is controversial due to their similar protein structures. In the present study, we aimed to investigate cross reactions with sheep’s, goat, and camel’s milks using skin prick test and atopy patch test in children with cow’s milk allergy. Materials and Methods: Our study group was composed of patients with atopic dermatitis who were diagnosed with cow’s milk allergy in our former study where we investigated the sensitivity of different diagnostic tests commonly used to determine cow’s milk allergy. In all patients, cow’s milk, sheep’s milk, goat’s milk and camel’s milk were used for skin prick test and atopy patch test. The study data were analyzed with SPSS 20.0 for Windows. Results: Among the patients with cow’s milk allergy, 15 (63%) had early-onset and 9 (37%) late-onset reactions with provocation tests. Seven (70%) of 10 children who were found skin prick test positive with cow’s milk were shown to have a cross reaction against goat’s and sheep’s milk with skin prick test; 8 (88.8%) of 9 children who were found to be atopy patch test positive with cow’s milk had a cross reaction against goat’s milk, and 7 (66.6%) against sheep’s milk. No patient with cow’s milk allergy had a cross reaction with camel’s milk with either skin prick test or atopy patch test. Conclusion: Our study demonstrated that a cross reaction occurs at a quite high rate between cow’s milk, sheep’s milk and goat’s milk as revealed by both skin prick testing and atopy patch test, whereas there was no demonstrable cross reaction between cow’s milk and camel’s milk by either method.
目的：使用其他哺乳动物的牛奶作为牛奶过敏的替代治疗方法是有争议的，因为它们的蛋白质结构相似。在本研究中，我们旨在通过皮肤点刺试验和特应性贴剂试验，研究牛奶过敏儿童与绵羊奶、山羊奶和骆驼奶的交叉反应。材料和方法：我们的研究组由特应性皮炎患者组成，他们在我们之前的研究中被诊断为牛奶过敏，我们调查了常用于确定牛奶过敏的不同诊断测试的敏感性。所有患者均采用牛奶、羊奶、羊奶和骆驼奶进行皮肤点刺试验和特应性斑贴试验。研究数据采用SPSS 20.0 for Windows进行分析。结果：在牛奶过敏患者中，15例（63%）经激发试验出现早发性反应，9例（37%）出现迟发性反应。10名被发现对牛奶皮肤点刺试验呈阳性的儿童中，有7名（70%）对羊奶和羊奶有交叉反应；在9名对牛奶过敏性斑贴试验呈阳性的儿童中，有8名（88.8%）对羊奶有交叉反应，7名（66.6%）对羊乳有交叉反应。在皮肤点刺试验或特应性斑贴试验中，没有牛奶过敏患者与骆驼奶发生交叉反应。结论：我们的研究表明，皮肤点刺试验和特应性斑贴试验都表明，牛奶、羊奶和羊奶之间的交叉反应发生率很高，而无论哪种方法，牛奶和骆驼奶之间都没有明显的交叉反应。
{"title":"Comparison of Cross Reactions Between Cow’s Milk and Other Mammals’ Milk Using Skin Prick Test and Atopy Patch Test in Children with Atopic Dermatitis and Cow’s Milk Allergy","authors":"Özlem Sancaklı, A. Yenigün, T. Tuncel","doi":"10.21911/AAI.441","DOIUrl":"https://doi.org/10.21911/AAI.441","url":null,"abstract":"Objective: The use of other mammals’ milk as an alternative treatment of cow’s milk allergy is controversial due to their similar protein structures. In the present study, we aimed to investigate cross reactions with sheep’s, goat, and camel’s milks using skin prick test and atopy patch test in children with cow’s milk allergy. Materials and Methods: Our study group was composed of patients with atopic dermatitis who were diagnosed with cow’s milk allergy in our former study where we investigated the sensitivity of different diagnostic tests commonly used to determine cow’s milk allergy. In all patients, cow’s milk, sheep’s milk, goat’s milk and camel’s milk were used for skin prick test and atopy patch test. The study data were analyzed with SPSS 20.0 for Windows. Results: Among the patients with cow’s milk allergy, 15 (63%) had early-onset and 9 (37%) late-onset reactions with provocation tests. Seven (70%) of 10 children who were found skin prick test positive with cow’s milk were shown to have a cross reaction against goat’s and sheep’s milk with skin prick test; 8 (88.8%) of 9 children who were found to be atopy patch test positive with cow’s milk had a cross reaction against goat’s milk, and 7 (66.6%) against sheep’s milk. No patient with cow’s milk allergy had a cross reaction with camel’s milk with either skin prick test or atopy patch test. Conclusion: Our study demonstrated that a cross reaction occurs at a quite high rate between cow’s milk, sheep’s milk and goat’s milk as revealed by both skin prick testing and atopy patch test, whereas there was no demonstrable cross reaction between cow’s milk and camel’s milk by either method.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41628716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hulya Ucaryilmaz, Ayça Emsen, Ahmet Hakan Dikener, Neriman Akdam, A. Unlu, H. Artaç
Objective: Periostin, an extracellular matrix protein, is related to the eosinophilic airway inflammation. There is no specific marker in allergen immunotherapy to evaluate clinical response. We aimed to investigate the serum periostin levels in the children who receive allergen immunotherapy. Materials and Methods: Sixteen patients between 8-18 years (12.7±2.8 years) with allergic rhinitis and/or asthma due to grass pollen hypersensitivity and 30 healthy subjects (11.7±2.6 years) were included. Demographic data, eosinophil counts, skin prick tests and the specific IgE levels of the patients are recorded. Symptom scores, visual analog scales, medication scores were determined and the serum periostin levels were measured in the beginning, 4th and 12th months of the allergen immunotherapy. Results: The symptom scores for rhinitis in the 4th month showed significant improvements in all of the patients (p<0.05). Nine patients with allergic rhinitis accompanied by asthma, showed significant improvements in 12th month symptom score for asthma (p=0.018). A significant correlation was detected between the initial serum periostin levels and the symptom scores for the eye (r=0.668, p=0.005). No significant difference was found in serum periostin levels between the patient and the control groups. There were no significant differences in serum periostin levels in 4th and 12th months compared to the ones in the beginning. Conclusion: In this study, there were no significant differences in serum periostin levels of children during the allergen immunotherapy. The association of serum periostin levels with symptom scores for the eye needs to be confirmed in more children with allergic rhinoconjunctivitis.
{"title":"The Effect of Allergen Immunotherapy on Serum Periostin Levels in Children with Allergic Rhinitis","authors":"Hulya Ucaryilmaz, Ayça Emsen, Ahmet Hakan Dikener, Neriman Akdam, A. Unlu, H. Artaç","doi":"10.21911/AAI.435","DOIUrl":"https://doi.org/10.21911/AAI.435","url":null,"abstract":"Objective: Periostin, an extracellular matrix protein, is related to the eosinophilic airway inflammation. There is no specific marker in allergen immunotherapy to evaluate clinical response. We aimed to investigate the serum periostin levels in the children who receive allergen immunotherapy. Materials and Methods: Sixteen patients between 8-18 years (12.7±2.8 years) with allergic rhinitis and/or asthma due to grass pollen hypersensitivity and 30 healthy subjects (11.7±2.6 years) were included. Demographic data, eosinophil counts, skin prick tests and the specific IgE levels of the patients are recorded. Symptom scores, visual analog scales, medication scores were determined and the serum periostin levels were measured in the beginning, 4th and 12th months of the allergen immunotherapy. Results: The symptom scores for rhinitis in the 4th month showed significant improvements in all of the patients (p<0.05). Nine patients with allergic rhinitis accompanied by asthma, showed significant improvements in 12th month symptom score for asthma (p=0.018). A significant correlation was detected between the initial serum periostin levels and the symptom scores for the eye (r=0.668, p=0.005). No significant difference was found in serum periostin levels between the patient and the control groups. There were no significant differences in serum periostin levels in 4th and 12th months compared to the ones in the beginning. Conclusion: In this study, there were no significant differences in serum periostin levels of children during the allergen immunotherapy. The association of serum periostin levels with symptom scores for the eye needs to be confirmed in more children with allergic rhinoconjunctivitis.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46017004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disease caused by hypersensitivity reactions to Aspergillus antigen. Studies on the efficacy of omalizumab treatment in patients diagnosed with ABPA are limited to case reports and small series. Our aim was to evaluate the effectiveness of omalizumab treatment in ABPA in addition to clinical, radiological and serological characteristics these patients. Materials and Methods: This study is a prospective observational one. It included clinical review of 15 patients diagnosed with ABPA and the successful omalizumab treatment of 5 of these patients. Patients receiving omalizumab therapy were assessed at baseline, after 1 year and 3 years of starting treatment. Results: 15 patients (9 males, 6 females, mean age: 48.26 ± 9.92 years) diagnosed as ABPA were enrolled. One patient had received antituberculosis medications prior to diagnosis. The mean serum total IgE level was 1665 ± 909 IU/mL. The most common finding in thorax high-resolution computed tomography was central bronchiectasis. Omalizumab treatment was started in five patients with asthma and ABPA who have failed to respond to Global Initiative for Asthma step 4 treatment. Conclusion: ABPA should be considered in patients with uncontrolled or severe asthma, despite appropriate asthmatic treatment. Recognizing ABPA is important, because early diagnosis can delay the development or prevent the bronchiectasis that causes fibrotic lung disease. Omalizumab is an effective therapy option in patients with asthma and ABPA who fail to respond to Global Initiative for Asthma step 4 treatment.
{"title":"Allergic Bronchopulmonary Aspergillosis: A Clinical Evaluation of 15 Patients and Successful Omalizumab Treatment of Five Patients","authors":"D. Ünal","doi":"10.21911/AAI.476","DOIUrl":"https://doi.org/10.21911/AAI.476","url":null,"abstract":"Objective: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disease caused by hypersensitivity reactions to Aspergillus antigen. Studies on the efficacy of omalizumab treatment in patients diagnosed with ABPA are limited to case reports and small series. Our aim was to evaluate the effectiveness of omalizumab treatment in ABPA in addition to clinical, radiological and serological characteristics these patients. Materials and Methods: This study is a prospective observational one. It included clinical review of 15 patients diagnosed with ABPA and the successful omalizumab treatment of 5 of these patients. Patients receiving omalizumab therapy were assessed at baseline, after 1 year and 3 years of starting treatment. Results: 15 patients (9 males, 6 females, mean age: 48.26 ± 9.92 years) diagnosed as ABPA were enrolled. One patient had received antituberculosis medications prior to diagnosis. The mean serum total IgE level was 1665 ± 909 IU/mL. The most common finding in thorax high-resolution computed tomography was central bronchiectasis. Omalizumab treatment was started in five patients with asthma and ABPA who have failed to respond to Global Initiative for Asthma step 4 treatment. Conclusion: ABPA should be considered in patients with uncontrolled or severe asthma, despite appropriate asthmatic treatment. Recognizing ABPA is important, because early diagnosis can delay the development or prevent the bronchiectasis that causes fibrotic lung disease. Omalizumab is an effective therapy option in patients with asthma and ABPA who fail to respond to Global Initiative for Asthma step 4 treatment.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47209292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Bilgir, R. Özdemir, P. Değirmenci, B. Dede, C. Kırmaz
Objective: Chronic urticaria (CU), which is mostly idiopathic, may also be a sign of an allergic or systemic disease. A variety of diseases and allergens that accompany CU have been reported in various studies. The aim of this study was to investigate the factors that play a role in the etiology of CU. Materials and Methods: The demographic and clinical data from 302 patients – aged over 18 years - who were being monitored for CU were recorded. Several tests were performed to analyze comorbidities such as infection, malignancy, and autoimmune and rheumatic diseases. Skin Prick Test (SPT) results and questionnaires were reviewed. Results: Two hundred and thirteen out of the 302 patients with a mean age of 40.26±14.3 years were females. The duration of CU was 43.30±62.60 months and 42.9% of the patients had comorbidities. The most common disease was autoimmune thyroiditis (13.9%). Fifty-five percent of the patients were sensitive to inhalant allergens, and 5% exhibited allergen positivity for food. The most common allergens were house (43.7%) dust mites. Allergen positivity was 37.2% in those with comorbidities, while it was 62.8% in those without any comorbidities and this relationship was statistically significant (p<0.05). Conclusion: This study showed that there was an association between house dust mite and CU dust sensitivity. House dust mite sensitivity may trigger CU.
{"title":"Clinical Features of Patients with Chronic Urticaria and the Results of the Skin Prick Tests","authors":"F. Bilgir, R. Özdemir, P. Değirmenci, B. Dede, C. Kırmaz","doi":"10.21911/AAI.437","DOIUrl":"https://doi.org/10.21911/AAI.437","url":null,"abstract":"Objective: Chronic urticaria (CU), which is mostly idiopathic, may also be a sign of an allergic or systemic disease. A variety of diseases and allergens that accompany CU have been reported in various studies. The aim of this study was to investigate the factors that play a role in the etiology of CU. Materials and Methods: The demographic and clinical data from 302 patients – aged over 18 years - who were being monitored for CU were recorded. Several tests were performed to analyze comorbidities such as infection, malignancy, and autoimmune and rheumatic diseases. Skin Prick Test (SPT) results and questionnaires were reviewed. Results: Two hundred and thirteen out of the 302 patients with a mean age of 40.26±14.3 years were females. The duration of CU was 43.30±62.60 months and 42.9% of the patients had comorbidities. The most common disease was autoimmune thyroiditis (13.9%). Fifty-five percent of the patients were sensitive to inhalant allergens, and 5% exhibited allergen positivity for food. The most common allergens were house (43.7%) dust mites. Allergen positivity was 37.2% in those with comorbidities, while it was 62.8% in those without any comorbidities and this relationship was statistically significant (p<0.05). Conclusion: This study showed that there was an association between house dust mite and CU dust sensitivity. House dust mite sensitivity may trigger CU.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45443921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atopic dermatitis is the most common skin disease seen during childhood. Other allergic diseases may accompany atopic dermatitis and increased IgE and peripheral blood eosinophilia are common findings. Patients with atopic dermatitis who do not respond to standard treatment measures should be reassessed for differential diagnosis. Early-onset, treatment resistant severe atopic dermatitis with recurrent infection history apart from the infections occurring due to defective skin integrity are the warning signs for an underlying primary immunodeficiency. Clinicians should always remember that atopic dermatitis may be the first finding of an underlying primer immunodeficiency in patients. The sooner the diagnosis is made, the more likely it will be to avoid complications and morbidity.
{"title":"Primary Immunodeficiencies Associated with Atopic Dermatitis","authors":"S. Esenboğa, B. Sekerel, I. Tezcan","doi":"10.21911/AAI.423","DOIUrl":"https://doi.org/10.21911/AAI.423","url":null,"abstract":"Atopic dermatitis is the most common skin disease seen during childhood. Other allergic diseases may accompany atopic dermatitis and increased IgE and peripheral blood eosinophilia are common findings. Patients with atopic dermatitis who do not respond to standard treatment measures should be reassessed for differential diagnosis. Early-onset, treatment resistant severe atopic dermatitis with recurrent infection history apart from the infections occurring due to defective skin integrity are the warning signs for an underlying primary immunodeficiency. Clinicians should always remember that atopic dermatitis may be the first finding of an underlying primer immunodeficiency in patients. The sooner the diagnosis is made, the more likely it will be to avoid complications and morbidity.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41836679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. B. Eltan, E. Kuçukosmanoglu, Abdülkadir Usta, O. Keskin
Urticaria (Hives) is a common skin disease which can affect patients’ quality of life negatively because of widespread involvement of the body and occasionally a chronic course. In recent years, the popularity of complementary and alternative therapies (TAT) has been increasing in chronic diseases. TAT practices are also increasing in the treatment of allergic/immunologic diseases. Some of these treatments have harmful consequences for patients. In this article, we report a chronic urticaria patient who received traditional cautery therapy implemented with a hot needle and emphasize the harmful effects that alternative treatment methods may cause from time to time.
{"title":"Urticaria in a 12-Year-Old Female Patient Undergoing Traditional Cautery Therapy: Case Report","authors":"S. B. Eltan, E. Kuçukosmanoglu, Abdülkadir Usta, O. Keskin","doi":"10.21911/AAI.397","DOIUrl":"https://doi.org/10.21911/AAI.397","url":null,"abstract":"Urticaria (Hives) is a common skin disease which can affect patients’ quality of life negatively because of widespread involvement of the body and occasionally a chronic course. In recent years, the popularity of complementary and alternative therapies (TAT) has been increasing in chronic diseases. TAT practices are also increasing in the treatment of allergic/immunologic diseases. Some of these treatments have harmful consequences for patients. In this article, we report a chronic urticaria patient who received traditional cautery therapy implemented with a hot needle and emphasize the harmful effects that alternative treatment methods may cause from time to time.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44657483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Demir, M. Olgac, Derya Unal, Raif Coşkun, A. Gelincik, B. Çolakoğlu, S. Büyüköztürk
Objective: No data exists about the perceptions of Turkish hereditary angioedema patients regarding the use of C1 inhibitor concentrate that has been used in the treatment of acute attacks for the last 7 years. Our aim was to evaluate patient opinions about the C1 inhibitor (C1-inh) concentrate and determine the level of satisfaction with this drug. Materials and Methods: Fifty-seven hereditary angioedema (HAE) patients who used C1-inh concentrate for their angioedema attacks were asked to complete a questionnaire which contained various questions related to demographic information, clinical features, and experiences with C1-inh concentrate use. Results: Sixty-five % of the patients were female and 94.7% of the patients had type 1 HAE. The mean curent age and age of diagnosis were 38.11±12.6 and 29.95±13.85 years, respectively. Thirteen patients did not have a family history. Forty patients were under prophylaxis (danazol n=39, tranexamic acid= 1). The mean duration of the C1-inh concentrate usage was 4.07±1.76 years. The patients had taken this drug 6 times over the past year on average. All patients stated that they experienced difficulties during injections with this medication in the emergency units due to a lack of awareness by health care professionals regarding both HAE and C1-inh concentrate. While 61.4% of the patients reported overall satisfaction about the efficacy of drug, 43.8% stated that this medication should have a more practical application; 52.6% proposed that the drug should be more accessible in hospital emergency rooms. Conclusion: Patients with HAE generally considered that C1-inh concentrate was effective in their attacks. However, this group of patients expressed concerns related to the medical personnel’s awareness about HAE as well as access to the medication.
{"title":"Opinions of Turkish Hereditary Angioedema Patients Regarding the Use of C1 Inhibitor Concentrate in the Treatment of Acute Attacks","authors":"S. Demir, M. Olgac, Derya Unal, Raif Coşkun, A. Gelincik, B. Çolakoğlu, S. Büyüköztürk","doi":"10.21911/AAI.439","DOIUrl":"https://doi.org/10.21911/AAI.439","url":null,"abstract":"Objective: No data exists about the perceptions of Turkish hereditary angioedema patients regarding the use of C1 inhibitor concentrate that has been used in the treatment of acute attacks for the last 7 years. Our aim was to evaluate patient opinions about the C1 inhibitor (C1-inh) concentrate and determine the level of satisfaction with this drug. Materials and Methods: Fifty-seven hereditary angioedema (HAE) patients who used C1-inh concentrate for their angioedema attacks were asked to complete a questionnaire which contained various questions related to demographic information, clinical features, and experiences with C1-inh concentrate use. Results: Sixty-five % of the patients were female and 94.7% of the patients had type 1 HAE. The mean curent age and age of diagnosis were 38.11±12.6 and 29.95±13.85 years, respectively. Thirteen patients did not have a family history. Forty patients were under prophylaxis (danazol n=39, tranexamic acid= 1). The mean duration of the C1-inh concentrate usage was 4.07±1.76 years. The patients had taken this drug 6 times over the past year on average. All patients stated that they experienced difficulties during injections with this medication in the emergency units due to a lack of awareness by health care professionals regarding both HAE and C1-inh concentrate. While 61.4% of the patients reported overall satisfaction about the efficacy of drug, 43.8% stated that this medication should have a more practical application; 52.6% proposed that the drug should be more accessible in hospital emergency rooms. Conclusion: Patients with HAE generally considered that C1-inh concentrate was effective in their attacks. However, this group of patients expressed concerns related to the medical personnel’s awareness about HAE as well as access to the medication.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48504489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Aytekin, Fatih Çölkesen, Ö. Ardeniz, Z. Caliskaner
Primary intestinal lymphangiectasia is a rare disorder which characterized by impaired small intestinal lymph drainage. There is loss of proteins from dilated lymphatic channels located in the mucosa, submucosa or subserosa which is results with loss of gammaglobulins and lymphocytes, leading to impaired humoral and cellular immunity. Herein, we present a 61-year-old patient with immunodeficiency secondary to Primary intestinal lymphangiectasia (PIL), in whom we could attain effective and stable IgG levels only by subcutaneous IgG replacement rather than intravenous IgG. Our experience suggests that Subcutaneous Immunoglobulin (SCIG) replacement resulted in more stable levels of IgG in the presented patient with PIL. We concluded that SCIG should be the preferred route of immunoglobulin replacement therapy in secondary hypogammaglobulinemia due to protein losing enteropathy, especially in PIL.
{"title":"Successful Immunoglobulin Replacement with Subcutaneous Immunoglobulin Therapy in a Patient with Primary Intestinal Lymphangiectasia","authors":"G. Aytekin, Fatih Çölkesen, Ö. Ardeniz, Z. Caliskaner","doi":"10.21911/aai.442","DOIUrl":"https://doi.org/10.21911/aai.442","url":null,"abstract":"Primary intestinal lymphangiectasia is a rare disorder which characterized by impaired small intestinal lymph drainage. There is loss of proteins from dilated lymphatic channels located in the mucosa, submucosa or subserosa which is results with loss of gammaglobulins and lymphocytes, leading to impaired humoral and cellular immunity. Herein, we present a 61-year-old patient with immunodeficiency secondary to Primary intestinal lymphangiectasia (PIL), in whom we could attain effective and stable IgG levels only by subcutaneous IgG replacement rather than intravenous IgG. Our experience suggests that Subcutaneous Immunoglobulin (SCIG) replacement resulted in more stable levels of IgG in the presented patient with PIL. We concluded that SCIG should be the preferred route of immunoglobulin replacement therapy in secondary hypogammaglobulinemia due to protein losing enteropathy, especially in PIL.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48166333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：